The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $43.41

Today's change+2.48 +6.06%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $43.41

Today's change+2.48 +6.06%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc Hits New 100-day High

Sarepta Therapeutics Inc closed up sharply Friday, rallying (U.S.)$2.48 or 6.06% to (U.S.)$43.41 and setting a new 100-day high. Over the last five days, shares have gained 23.15% and 58.26% year to date. Shares have outperformed the S&P 500 by 77.46% during the last year.

Key company metrics

  • Open(U.S.) $41.55
  • Previous close(U.S.) $40.93
  • High(U.S.) $44.07
  • Low(U.S.) $41.49
  • Bid / Ask(U.S.) $42.85 / (U.S.) $43.43
  • YTD % change+58.26%
  • Volume7,600,116
  • Average volume (10-day)3,688,790
  • Average volume (1-month)2,252,374
  • Average volume (3-month)2,029,162
  • 52-week range(U.S.) $22.33 to (U.S.) $63.73
  • Beta1.18
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.44
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.53%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue16500
Total other revenue--------
Total revenue16500
Gross profit165----
Total cost of revenue00----
Total operating expense56945762
Selling / general / administrative26232218
Research & development29713444
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-39-88-57-62
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets125------
Other--------
Income before tax86-88-57-62
Income after tax84-88-57-62
Income tax, total2------
Net income84-88-57-62
Total adjustments to net income--------
Net income before extra. items84-88-57-62
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items84-88-57-62
Inc. avail. to common incl. extra. items84-88-57-62
Diluted net income84-88-57-62
Dilution adjustment--------
Diluted weighted average shares56554846
Diluted EPS excluding extraordinary itemsvalue per share1.50-1.62-1.18-1.35
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.05-1.62-1.18-1.35